Pharming Group N.V. Investigation - PHAR

Company
Pharming Group N.V. (NASDAQ: PHAR)

Learn more about the Pharming Group N.V. Investigation

Required Field

Required Field

Required Field

  • $1 - $1,000
  • $1001 - $10,000
  • $10,001 - $25,000
  • $25,001 - $50,000
  • $50,001 - $100,000
  • $100,001 - $250,000
  • $250,001 - $500,000
  • $500,000+

There is no cost or obligation for you to submit.

The submission of this form does not create an attorney-client relationship.

Please Upload related files below

Add Transactions

Purchases

1.
  • Common Stock
  • Preferred Stock
  • Bonds
  • Calls
  • Puts
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12

Additional Purchases

Sales

1.
  • Common Stock
  • Preferred Stock
  • Bonds
  • Calls
  • Puts
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12

Additional Sales

Please input at least 1 transaction or press "skip for now" button below

Please fill in all the fields for your transaction or press "skip for now" button below

Alternatively, you may upload your transactions below or e-mail them to [email protected]

Upload Your Stock Tickers

Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. SnapTrade only shares the tickers you own and your transaction history, not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.

Don’t miss out on possible monetary recovery - link your brokerage account with SnapTrade.

Skip

Pharming Group N.V. Investigation Details

Pharming Group stock dropped 22% on July 30, 2026, after the Company reported second-quarter revenue of $90.2 million -- down 3% year-over-year -- and cut its full-year 2026 revenue guidance to $375-$395 million from $405-$425 million. The revenue shortfall was primarily driven by RUCONEST, the Company's legacy hereditary angioedema therapy. RUCONEST sales fell 10% year-over-year to $72.3 million in the quarter. Joenja revenue rose 40% to $17.9 million. Diluted EPS came in at $0.002, versus $0.006 in the prior-year period. The reduced FY 2026 outlook sits roughly $30 million below the prior midpoint and below analyst consensus of approximately $419 million. This investigation concerns whether Pharming Group and certain of its officers may not have adequately disclosed competitive and demand pressures affecting RUCONEST prior to the July 30, 2026 announcement.

Get Started